Idazoxan

Drug Profile

Idazoxan

Alternative Names: CGP 25811A; RX 781094

Latest Information Update: 04 Aug 2015

Price : $50

At a glance

  • Originator Reckitt Benckiser
  • Developer Pierre Fabre; Potomac Pharma; Reckitt Benckiser
  • Class Antipsychotics; Dioxanes; Imidazoles; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cognition disorders; Major depressive disorder; Neurological disorders; Parkinson's disease; Schizophrenia; Type 1 diabetes mellitus

Most Recent Events

  • 22 Jan 2001 Discontinued-Clinical for Cognition disorders in United Kingdom (Unknown route)
  • 22 Jan 2001 Discontinued-Clinical for Type-1 diabetes mellitus (IV-infusion)
  • 22 Jan 2001 Discontinued-Phase-Unspecified for Schizophrenia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top